Active Biotech Appoints Erik Vahtola as Chief Medical Officer
Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the executive management team and be responsible for the development of the company´s clinical project portfolio within solid and hematological cancers, and inflammatory eye disorders.
Dr. Vahtola has more than 10 years of experience altogether from regulatory authority and pharma industry positions within clinical development and medical affairs. Before joining Active Biotech, he has worked at Bayer Pharmaceuticals, Orion Corporation and Roche Pharma, Finland. As a Medical Doctor (MD) he has experience from working as a specializing physician in oncology at the Helsinki University Central Hospital, Finland and he holds a PhD in pharmacology and an MSc in cell biology from Åbo Akademi University, Finland.
“We are happy to welcome Erik to Active Biotech. This appointment marks an important step in the continued development of the company's project portfolio with three projects now in clinical development. Erik’s medical expertise and experience will further strengthen the team as our project portfolio progresses into later clinical phases”, said Dr. Helén Tuvesson, CEO of Active Biotech.
“I am excited to join Active Biotech at this important stage, where the company has advanced the clinical development of its exciting leading candidate drugs in both oncology and inflammatory eye diseases”, said Erik Vahtola.
Dr. Helena Eriksson, CSO and responsible for Research and Development since 2017, has decided to leave her position after 23 years in the company, but she will continue as a consultant to Active Biotech with a focus on scientific and patent-related issues.
“Helena, with her deep biological understanding, has been instrumental in the implementation of the company's new focus on projects in specialist indications with high medical need and a commercial opportunity. I would like to thank Helena for her commitment and engagement in the development of our projects, and I am very happy that we will continue to work together”, said Helen Tuvesson.
For further information, please contact:
Helén Tuvesson, CEO, +46 46 19 21 56, firstname.lastname@example.org
Hans Kolam, CFO, +46 46 19 20 44, email@example.com
About Active Biotech
Active Biotech AB (publ) (NASDAQ Stockholm: ACTI) is a biotechnology company that deploys its extensive knowledge base and portfolio of compounds to develop first-in-class immunomodulatory treatments for specialist oncology and immunology indications with a high unmet medical need and significant commercial potential. Following a portfolio refocus, the business model of Active Biotech aims to advance projects to the clinical development phase and then further develop the programs internally or pursue in partnership. Active Biotech currently holds three projects in its portfolio: Naptumomab, a targeted anti-cancer immunotherapy, partnered to NeoTX Therapeutics, is in a phase Ib/II clinical program in patients with advanced solid tumors. The small molecule immunomodulators, tasquinimod and laquinimod, both having a mode of actions that includes modulation of myeloid immune cell function, are targeted towards hematological malignancies and inflammatory eye disorders, respectively. Tasquinimod, is in clinical phase Ib/IIa for treatment of multiple myeloma. Laquinimod is in a clinical phase I study with a topical ophthalmic formulation, to be followed by phase II for treatment of non-infectious uveitis. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Scheelevägen 22, SE-223 63 Lund, Sweden
Tel: +46 (0)46 19 20 00
This information is information was submitted for publication, through the agency of the contact person set out above, at 14.00 pm CET on January 4, 2022.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Winners Announced in the Seventh Annual Stevie® Awards for Great Employers8.8.2022 15:00:00 CEST | Press release
Top Winners Include IBM and Tata Consultancy Services FAIRFAX, Va., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Winners in the 2022 (seventh annual) Stevie® Awards for Great Employers, an international competition, were announced today. The awards recognize the world’s best employers and the human resources professionals, teams, achievements, and HR-related products and suppliers who help to create and drive great places to work. Among the organizations with the most Stevie-winning nominations are IBM, worldwide (27 Gold, Silver, and Bronze wins), Tata Consultancy Services, worldwide (23), Enerjisa Enerji, Turkey (21), Bank of America, USA (18), Cathay United Bank, Taiwan (10), Globe Telecom, Inc., Philippines (10), MİGROS, Turkey (10), Abu Dhabi Customs, United Arab Emirates (8), DHL Global Forwarding, Germany (8), Sabanci Holding, Turkey (8), İGA (İstanbul Grand Airport), Turkey (7), Megaphone, Australia (7), and NEQSOL HOLDING, Azerbaijan (7). Visit www.StevieAwards.com/HR for a full list of
J.M. Huber Corporation Signs Agreement to Acquire the Biolchim Group From NB Renaissance, Chequers Capital and Management Team8.8.2022 15:00:00 CEST | Press release
ATLANTA, Aug. 08, 2022 (GLOBE NEWSWIRE) -- J.M. Huber Corporation (Huber)—a global, family-owned specialty engineered materials manufacturing company—announced today that it has signed a binding agreement to acquire full control of the Biolchim Group from NB Renaissance, Chequers Capital and the Biolchim Group management team. The Biolchim Group, managed and headed by Galileo Quattro SARL, has its main operating base in Italy and is a leading producer and distributor of a full range of specialty plant nutrition and biostimulants. Closing of the sale, anticipated to occur by the end of 2022, is subject to customary closing conditions including the foreign direct investment approval in Italy. All the companies in the Biolchim Group—including Biolchim S.p.A, Cifo, Ilsa S.p.A, Matécsa Kft, and West Coast Marine-Bio Processing Corp.—are within the scope of the purchase. The Biolchim Group operates eight production plants globally and its products—biostimulants, trace elements, and water sol
Bombardier Announces Firm Order for the First Challenger 3500 Business Jet based in Europe for Charter Operations with Air Corporate SRL8.8.2022 14:00:00 CEST | Press release
Italian-based Air Corporate SRL to be the first European operator to offer the Challenger 3500 business jet for charter services, which will join the company’s fleet of aircraft With its innovative technology, redesigned cabin and sustainably minded features, the Challenger 3500 business jet is ideally suited for the European charter market MONTREAL, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Bombardier today announced the sale of its industry-leading Challenger3500 business jet to Italian-based operator, Air Corporate SRL. This will be the first company to offer the aircraft for charter in Europe. Introduced in 2021, the new Challenger 3500 aircraft offers a unique blend of performance, advantageous operating costs, ultimate cabin experience and smooth ride, making it an ideal choice for the European charter market. And with its redesigned interior with intelligent and sustainably minded cabin features, the Challenger 3500 aircraft is elegantly crafted to combine comfort with function, fully e
RCI Banque: the " Half-Yearly Financial Report 2022" is now available one the website8.8.2022 11:54:30 CEST | Press release
August 8th, 2022 The "EMTN Semi-Annual Report 2022" is now available on the website www.mobilize-fs.com Attachment RCI Banque_Financial Report (emtn) 06.2022
RCI Banque: The EMTN Semi-Anual Report 2022 is now available8.8.2022 11:49:31 CEST | Press release
August 8th,2022 "The EMTN Semi-Annual Report 2022" is now available on the website www.mobilize-fs.com Attachment Communiqué de publication - The emtn semi annnual report 2022 is now available